River Road Asset Management LLC slashed its stake in Amgen Inc. (NASDAQ: AMGN) by 40.7% in fourth quarter,now holding 22,044 shares valued around $7.21 million . That's a big drop from 112,000 shares.
Other institutional investors made moves too. Robeco Institutional Asset Management B.V. bumped up its stake by 10%,adding 43,884 shares to total 481,453 shares,worth $157.58 million. Meanwhile,Curtis Advisory Group LLC opened a new position worth $1.67 million in same period.
Adell Harriman & Carpenter Inc. upped its holdings in Amgen by 7.9%,now owning 22,008 shares worth $7.20 million after buying 1,609 more. Fideuram Intesa Sanpaolo Private Banking S.P.A . entered market with a new stake valued at $22.44 million . Sigma Planning Corp increased investment by 24%,now holding 17,992 shares worth $5.89 million after purchasing 3,488 shares.
Institutional investors control 76.5% of Amgen’s stock. Friday,Amgen shares opened at $337.60,contributing to market cap of $182.21 billion. Company shows a P/E ratio of 23.49,beta of 0.42. Debt-to-equity ratio at 5.65,with current and quick ratios of 1.26 and 1.01. Past year,stock swung between $267.83 low to $391.29 high.
Latest earnings report from April 30 shows Amgen's EPS hit $5.15,beating analysts' $4.77 expectations. Revenue reached $8.62 billion,just over $8.58 billion forecast. Return on equity was 137.41%,net margin 20.96%,with 5.8% year-over-year revenue growth. For fiscal year 2026,Amgen expects EPS between 21.70 and 23.10,while analysts estimate 22.38 EPS for current year.
Analysts split on Amgen. Wells Fargo & Company hiked target price from $375 to $390,keeping “equal weight” rating. Canaccord Genuity Group started coverage with “hold” rating,price target $366. Erste Group Bank reaffirmed “hold” rating. Morgan Stanley adjusted price objective from $332 to $340,also rating stock as “equal weight.” Truist Financial set new price target of $327,maintaining “hold” rating.
Currently,two analysts rate Amgen “Strong Buy,” twelve say “Buy,” while fifteen assign “Hold” rating. Two issued “Sell.” Average rating stands at “Hold,” with consensus price target of $354.42.
In insider trading,Nancy A. Grygiel,senior VP at Amgen,sold 1,237 shares May 4 at average price of $323.73,totaling $400,454.01. After this,Grygiel holds 7,009 shares valued about $2.27 million,marking 15% drop in her position. Insiders own 0.85% of Amgen’s stock.
Founded in 1980,headquartered in Thousand Oaks,California,Amgen Inc. is big player in global biotech. Specializes in developing,manufacturing human therapeutics for serious illnesses. Focuses on biologic medicines from cellular,molecular biology…
